<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) involvement in non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) is a well-recognised complication </plain></SENT>
<SENT sid="1" pm="."><plain>There is no consensus regarding indications for prophylaxis or a standard <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> chemoprophylaxis regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Current UK practice was evaluated using a questionnaire </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 223 questionnaires were sent to clinicians who administered chemotherapy to patients with NHL; 158 (71%) evaluable questionnaires were returned </plain></SENT>
<SENT sid="4" pm="."><plain>The overwhelming majority of respondents used prophylaxis in <z:hpo ids='HP_0000001'>all</z:hpo> cases of lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (97%) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (96%) </plain></SENT>
<SENT sid="5" pm="."><plain>Ninety-six per cent of respondents required risk factors to be present before prophylaxis was initiated in cases of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The commonest risk factor was site of involvement (paranasal sinus 88%, testicular 85%, orbital cavity 78%, bone marrow 65% and bone 28%) </plain></SENT>
<SENT sid="7" pm="."><plain>Other risk factors included stage IV, high International Prognostic Index score, &gt;1 extranodal site and raised <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase levels (34%, 21%, 16% and 10%) </plain></SENT>
<SENT sid="8" pm="."><plain>A total of 82% did not give prophylaxis in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 90% used intrathecal chemotherapy as their preferred method of prophylaxis </plain></SENT>
<SENT sid="9" pm="."><plain>The most popular regimen was 12.5 mg <z:chebi fb="0" ids="44185">methotrexate</z:chebi> with each cycle of chemotherapy for six courses </plain></SENT>
<SENT sid="10" pm="."><plain>Thirty-nine per cent used systemic chemotherapy for <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis either alone (4%) or as an adjunct to intrathecal prophylaxis (35%) </plain></SENT>
<SENT sid="11" pm="."><plain>These variations in the indications and methods of prophylaxis indicate that this subject deserves further review </plain></SENT>
</text></document>